On September 6, 2022 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, reported members of its management team will participate at the following investor conferences in September 2022 (Press release, Alpine Immune Sciences, SEP 6, 2022, View Source [SID1234619046]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 24th Annual Global Investment Conference
Date: Monday, September 12, 2022
Time: 7:00 a.m. PT/10:00 a.m. ET
Event: Corporate Presentation & One-on-One Investor Meetings
Presenter: Remy Durand, PhD, Chief Business Officer, Alpine Immune Sciences, Inc.

Morgan Stanley 20th Annual Global Healthcare Conference
Date: Wednesday, September 14, 2022
Event: One-on-One Investor Meetings

A link to the H.C. Wainwright corporate presentation will be available online in the investor relations section of the Company’s website at View Source and will be available on the Company website for 90 days following the webcast. Investors interested in participating in One-on-One meetings at these conferences should reach out to their sales representatives at H.C. Wainwright and Morgan Stanley for more information.

On September 6, 2022 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported that it will present at the Morgan Stanley 20th Annual Global Healthcare Conference at 10:35 a.m. Eastern Time on Tuesday, September 13, 2022 in New York (Press release, Neurocrine Biosciences, SEP 6, 2022, View Source [SID1234619045]). Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live presentation will be webcast and may be accessed on the Company’s website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

On September 6, 2022 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported that senior leadership plans to present at the following conferences in September (Press release, Iovance Biotherapeutics, SEP 6, 2022, View Source [SID1234619044]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo Healthcare Conference
Fireside Chat: September 7 at 2:35 p.m. ET
Boston, MA
HC Wainwright Annual Global Investment Conference
Presentation: On demand beginning September 12 at 7:00 a.m. ET
Virtual and New York, NY
Baird Global Healthcare Conference
Fireside Chat: September 13 at 9:40 a.m. ET
New York, NY
Cantor Oncology, Hematology & HemeOnc Conference
Panel: Cell Therapy in Solid Tumors, September 28 at 1:45 p.m. ET
New York, NY
The live and archived webcasts will be available at View Source

On September 6, 2022 NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, reported that compassionate use cases of SNK01 + an immune checkpoint inhibitor in patients with advanced sarcoma have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Congress being held in Paris, France, September 9 – 13, 2022 (Press release, NKMax America, SEP 6, 2022, View Source [SID1234619043]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation

Title: USFDA Authorized Compassionate Use of SNK01 (Autologous Non-Genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) and Checkpoint Inhibitors in Advanced Heavily Pre-treated Sarcoma: A Promising Regimen.
Poster #: P757
Date and Time: September 10, 2022, 10:38 am CEST
Poster Session: 13
Location: Paris Expo Porte de Versailles; Poster Area, Hall 4

Promising data aggregated from eight USFDA approved compassionate use IND cases from metastatic sarcoma patients who received SNK01 combined with a checkpoint inhibitor will be disclosed during the poster presentation. The combination of SNK01 and a checkpoint inhibitor appears to have clinical activity against several types of heavily pre-treated advanced sarcomas, independent of PD-L1 status. The data also suggests that repeated dosing with the combination appears to be safe and well-tolerated.

More information on the ESMO (Free ESMO Whitepaper) Congress 2022 can be found at the following link: View Source

On September 6, 2022 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported that senior company representatives will participate in the following scientific conferences during September 2022 (Press release, Alligator Bioscience, SEP 6, 2022, View Source [SID1234619042]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ESMO Congress 2022, September 9 – 13, Paris
Malin Carlsson, Executive Vice President & Chief Operating Officer at Alligator Bioscience, and Karin Nordbladh, Director of Clinical Operations at Alligator Bioscience, to attend in-person.
Registration for the conference is open here.
AACR Special Conference on Pancreatic Cancer, September 13 – 16, Boston
Yago Pico de Coaña, Medical Science Director at Alligator Bioscience, to present complete data from the Phase 1b dose escalation part of mitazalimab OPTIMIZE-1 Phase 1b/2 trial in first-line metastatic pancreatic cancer.
Registration for the conference is open here.
13th World Bispecific Summit, September 20 – 22, Boston
Laura von Schantz, Vice President of Discovery at Alligator Bioscience, to give a presentation entitled "Kick-Starting Tumor Specific T Cell Cross-Priming Using Neo-X-Prime Bispecific Antibodies Targeting CD40" at 01:45 pm EDT / 07:45 pm CEST on September 21.
Registration for the conference is open here.
Immuno UK, September 29-30, London
Peter Ellmark, Chief Scientific Officer at Alligator Bioscience, will give a presentation entitled "Targeting the Myeloid Population In The Tumour Microenvironment" at 01:45 pm BST / 2:45 pm CEST on September 30.
Registration for the conference is open here.